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CXCL12 is a chemotactic cytokine that attracts many different cell types for homeostasis
and during inflammation. Under stress conditions, macrophages and granulocytes
produce factors such as peroxynitrite as a consequence of their oxidative response.
After short incubations of CXCL12 with peroxynitrite, the gradual nitration of Tyr7, Tyr61,
or both Tyr7 and Tyr61 was demonstrated with the use of mass spectrometry, whereas
longer incubations caused CXCL12 degradation. Native CXCL12 and the nitrated forms,
[3-NT61]CXCL12 and [3-NT7/61]CXCL12, were chemically synthesized to evaluate the
effects of Tyr nitration on the biological activity of CXCL12. All CXCL12 forms had a
similar binding affinity for heparin, the G protein-coupled chemokine receptor CXCR4
and the atypical chemokine receptor ACKR3. However, nitration significantly enhanced
the affinity of CXCL12 for chondroitin sulfate. Internalization of CXCR4 and β-arrestin
2 recruitment to CXCR4 was significantly reduced for [3-NT7/61]CXCL12 compared
to CXCL12, whereas β-arrestin 2 recruitment to ACKR3 was similar for all CXCL12
variants. [3-NT7/61]CXCL12 was weaker in calcium signaling assays and in in vitro
chemotaxis assays with monocytes, lymphocytes and endothelial cells. Surprisingly,
nitration of Tyr61, but not Tyr7, partially protected CXCL12 against cleavage by the
specific serine protease CD26. In vivo, the effects were more pronounced compared to
native CXCL12. Nitration of any Tyr residue drastically lowered lymphocyte extravasation
to joints compared to native CXCL12. Finally, the anti-HIV-1 activity of [3-NT7]CXCL12
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and [3-NT7/61]CXCL12 was reduced, whereas CXCL12 and [3-NT61]CXCL12 were
equally potent. In conclusion, nitration of CXCL12 occurs readily upon contact with
peroxynitrite and specifically nitration of Tyr7 fully reduces its in vitro and in vivo biological
activities.
Keywords: chemokine, post-translational modification, inflammation, nitration, lymphocyte migration
INTRODUCTION
CXCL12 is a homeostatic CXC chemokine that exists in six
splice variants and is expressed in most tissues (1). Initially,
CXCL12 was discovered as a pre-B cell growth factor of
crucial importance for lymphopoiesis and embryogenesis and
was shown to be a co-stimulator for CD4+ T cell activation
(2, 3). Regarding its chemotactic activity, CXCL12 was purified
from its main source, the bone marrow stroma, based on
its ability to attract lymphocytes and monocytes (4). In the
bone marrow, CXCL12 prevents the release of hematopoietic
progenitor cells into the circulation (5). Furthermore, CXCL12
is an angiogenic chemokine and attracts endothelial progenitor
cells in response to hypoxia (6). CXCL12 activity has also been
shown in several inflammatory conditions, such as rheumatoid
arthritis, inflammatory bowel disease and cancer growth and
metastasis (3, 7, 8).
To fulfill these functions, CXCL12 activates its 7-
transmembrane spanning (7TM) G protein-coupled receptor
(GPCR) CXCR4 and atypical chemokine receptor ACKR3
(9–11). As is the case for CXCL12, CXCR4 knock-out mice die
perinatally due to defects in lymphopoiesis and neurogenesis
(2, 12). ACKR3 knock-out mice show defects in their cardiac and
lymphatic vascular development and die post-natally (13, 14).
CXCR4, with CXCL12 as its only chemokine ligand, is present
on the cell membrane of most cell types. CXCL12 can therefore
activate not only most leukocyte types, but also hematopoietic
stem and progenitor cells, epithelial cells and endothelial cells
(15–17). ACKR3 is an atypical receptor since it does not initiate
signal transduction by the activation of G proteins, but by the
recruitment of β-arrestins to the cell membrane (18). It binds
CXCL12 and CXCL11 with high affinity and is expressed on
hematopoietic cells, embryonic neuronal and cardiac tissues and
activated endothelium (10, 19). Activation of ACKR3 leads to
migration of neuronal progenitor cells and an increased cellular
survival and adhesion (10, 20). Moreover, ACKR3 functions as
a sink for CXCL12 and removes it from the environment, thus
modifying chemokine gradients (21). To form these gradients,
CXCL12 binds to negatively charged glycosaminoglycan (GAG)
polymers on cell surfaces and in the extracellular matrix (22).
Since CXCL12 and its receptors are present throughout the
body, its activity in homeostasis and inflammation needs to be
thoroughly controlled. Several post-translational modifications
have been described to reduce or completely abolish CXCL12
activity, including enzymatic NH2- and COOH-terminal
truncation, Arg citrullination by peptidyl arginine deiminase
(PAD) and Tyr nitration (23–26). Removal of NH2-terminal
amino acids occurs by dipeptidyl peptidase-4 (DPP-4) or CD26,
neutrophil elastase, cathepsin G and multiple members of
the matrix metalloproteinase (MMP) family and inactivates
CXCL12. COOH-terminal truncation occurs by the circulating
carboxypeptidase N and the membrane-bound carboxypeptidase
M, and reduces CXCL12 activity (23, 24). Most of these truncated
CXCL12 forms have been detected in human plasma (27). The
administration of the CXCR4 inhibitor AMD3100 together with
granulocyte-colony stimulating factor (G-CSF) is a commonly
used method to release progenitor cells from the bone marrow
into the circulation. AMD3100 interrupts the interaction of
CXCL12 with CXCR4, and CXCL12 is inactivated due to the
induction of CD26 and neutrophil elastase by G-CSF (28, 29).
In vitro citrullination of CXCL12 by incubation with PAD
occurred rapidly and resulted in a reduced or abolished activity,
depending on the number of citrullinated arginine residues.
Co-localization of CXCL12 and PAD in biopsies of Crohn’s
disease patients suggests that this modification occurs in vivo
(25).
Recently, nitration of both Tyr residues of CXCL12 by
peroxynitrite was described (30). We noticed that CXCL12
may be degraded further by incubation with peroxynitrite.
Additionally, we detected natural nitration of Tyr7 in the
supernatant of co-cultures of CXCL12-producing bone marrow
stromal cells and leukocytes under inflammatory conditions (26).
Nitration of Tyr7 resulted in reduced calcium signaling, in vitro
lymphocyte and monocyte chemotaxis and in vivo lymphocyte
recruitment (26). In this study, we aimed to detect the nitrated
amino acids of intact, non-degraded CXCL12 after incubation
with peroxynitrite. CXCL12 variants with a nitrated Tyr61 were
identified, synthesized and functionally evaluated in vitro and
in vivo. Since CXCR4 is a main co-receptor for HIV-1 infection
and CXCL12 functions as a natural competitor for HIV-1, we
also tested the effects of nitration on the anti-HIV-1 capacity of
CXCL12 (9). Finally, we evaluated the different nitrated CXCL12
variants in a chemotaxis assay with microvascular endothelial
cells to reveal possible effects on angiogenesis.
MATERIALS AND METHODS
Cells
Chinese hamster ovary (CHO) cells, transfected with CXCR4
or ACKR3, were kindly provided by Prof. Dr. M. Parmentier
from the Institute of Interdisciplinary Research in Human
and Molecular Biology (IRIBHM) at the Université Libre
de Bruxelles, Brussels, Belgium. CHO cells were cultivated
in Ham’s F-12 growth medium (Lonza, Basel, Switzerland)
including 10% (v/v) FBS, 400µg/ml G418 (Gibco, Auckland,
New Zealand) and 250µg/ml zeocin (Invitrogen, Carlsbad,
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CA). Human monocytic THP-1 cells (American Type Culture
Collection, Manassas, VA, USA) were cultured in Roswell Park
Memorial Institute medium 1640 with glutamine supplement
(RPMI 1640–GlutaMAX; Gibco), which was further enriched
with 10% (v/v) FBS and 3% (w/v) sodium bicarbonate. THP-1
and CHO cells were subcultivated 2 days prior to the signaling
or cell migration assays. The C2C12 mouse myoblast cell line,
stably transfected with CXCR4, was obtained from DiscoverX
(Fremont, CA) and was cultured in Dulbecco’s Modified Eagle’s
Medium 1885 (DMEM; Gibco), containing 20% (v/v) FBS, 1%
(v/v) penicillin/streptomycin, 1% (v/v) L-glutamine, 500µg/ml
hygromycin B (Invitrogen) and 1,000µg/ml G418 (Gibco). U2OS
cells (ATCC) were cultured in Minimal Essential Medium alpha
(MEM-alpha; Gibco) supplemented with 10% (v/v) FBS, 1% (v/v)
L-glutamine, 1% (v/v) penicillin/streptomycin and 500µg/ml
hygromycin B. CV-1 in Origin with SV40 genes-7 (COS-
7) cells (ATCC) were grown in DMEM 1885, supplemented
with 10% (w/v) FBS, 1% (v/v) penicillin/streptomycin (Gibco)
and 1% L-glutamine at 10% CO2 and 37
◦C. Human retinal
microvascular endothelial cells (HRMVE; Cell Systems, Kirkland,
WA, USA) were cultivated in endothelial basal medium-2 (EBM-
2) with endothelial growthmedium-2MV (EGM2-MV) BulletKit
supplement (Lonza). HRMVE cells were used at passage numbers
between 5 and 8. Lymphocytes were isolated from buffy coats
that were freshly provided by the Belgian Red Cross (Mechelen,
Belgium) as previously described (31). Human lymphocytic MT-
4 cells were cultured in RPMI 1640 (Gibco), supplemented with
10% (v/v) FBS. Unless stated otherwise, all cells were cultured at
5% CO2 and 37
◦C.
Chemical Synthesis of CXCL12 and
Nitrated Variants
Native CXCL12 and its nitrated variants with a nitrotyrosine at
position 7 or 61 or at both positions 7 and 61 were chemically
synthesized using fluorenyl methoxycarbonyl (Fmoc) chemistry
on an Activo-P11 solid phase peptide synthesizer (Activotec,
Cambridge, UK) and subsequently deprotected, purified and
folded as described previously (26).
Chemical Nitration of CXCL12
Synthetic CXCL12 was incubated with several concentrations
of peroxynitrite (Cayman Chemical Company, Ann Arbor,
MI, USA) at room temperature or 37◦C for 1min in a final
volume of 30 µl ultrapure water. The reaction was stopped by
adding 20 µl of 1% (v/v) trifluoroacetic acid (TFA; Biosolve,
Valkenswaard, The Netherlands). Samples were injected from
this reaction vial onto a Proto 300 C4 column (5µm, 50
× 0.15mm; Higgins Analytical, Mountain View, CA, USA),
equilibrated with 0.1% (v/v) TFA and 4% (v/v) acetonitrile in
ultrapure water. Elution occurred by reversed-phase ultra-high
performance liquid chromatography (RP-UPLC; UltiMate 3000
RSLC; Thermo Scientific, Waltham, MA, USA), using a linear 0–
80% acetonitrile gradient in 0.1% (v/v) formic acid. The location
of nitrated Tyr in non-degraded CXCL12 was identified by
detecting specific MS2 signature fragments in the eluate using
an ion trap mass spectrometer (Amazon Speed ETD; Bruker
Daltonics, Bremen, Germany).
Glycosaminoglycan Binding Properties
The affinity of the different CXCL12 forms for heparin (Iduron,
Macclesfield, UK) or chondroitin sulfate (Iduron) was measured
with a previously described ELISA-like assay in GAG-binding
plates (BD Biosciences, Franklin Lakes, NJ, USA) or by surface
plasmon resonance (Biacore T200 instrument; GE Healthcare,
Uppsala, Sweden) (32).
CXCR4 Binding and Internalization
Binding of CXCL12 and its nitrated variants to CHO cells
transfected with CXCR4 was investigated in a competition
assay using CXCL12AF647 (Almac, Craigavon, Northern Ireland),
as described previously (25). Internalization of CXCR4 after
stimulation of CXCR4 transfected CHO cells or THP-1 cells with
the CXCL12 variants was determined by detecting the remaining
CXCR4 expression using specific phycoerythrin-labeled CXCR4
antibodies (Clone 12G5, BD Biosciences) or mouse anti human
CXCR4 antibody clone 44717 (R&D Systems, Minneapolis,
MN, USA) in combination with phycoerythrin-labeled goat
anti mouse antibodies (BD Biosciences) and flow cytometry
(FACSCalibur flow cytometer) (26).
Signal Transduction Experiments
β-arrestin 2 recruitment to CXCR4 or ACKR3 after stimulation
with the CXCL12 variants was tested in C2C12 cells, stably
transfected with CXCR4, or U2OS cells, transiently transfected
with ACKR3, respectively, using the β-galactosidase fragment
complementation technology (PathHunter β-arrestin assay,
DicoveRx) (26).
Calcium mobilization in THP-1 and CXCR4-transfected
CHO cells was measured using the fluorescent calcium-
binding dye Fura-2 (Molecular Probes, Invitrogen) on a LS50B
spectrofluorimeter (PerkinElmer, Waltham, MA, USA) (33).
Phosphorylation of Akt and ERK1/2 was measured in cell
lysates of CXCR4-transfected CHO cells stimulated at 37◦C with
the CXCL12 variants using specific phospho-Akt (S473) and
phospho-ERK1(T202/Y204)/ERK2(T185/Y187) ELISA duosets
(R&D Systems). The ratio of the concentration of phosphorylated
kinase over the total amount of protein was calculated for each
sample and depicted as percentage of unstimulated control.
The inositol turnover assay was performed with COS-7 cells,
transiently transfected with CXCR4, by measuring the amount of
radioactive inositol in the cytoplasm after stimulation of the cells
with the CXCL12 variants, as previously described (26).
Chemotaxis Assays
Migration of THP-1 cells toward different CXCL12 variants was
tested in 96-well multiscreen plates (Millipore, Billerica, MA,
USA). Migrated cells were quantified as previously described
using the ATPlite kit (PerkinElmer) (34). Chemotactic indices
were calculated as the ratio of the luminescence intensity of cells
migrated toward the test sample over the luminescence intensity
of cells migrated toward chemotaxis buffer alone.
Lymphocyte chemotaxis in Boyden microchambers using
fresh, unfractionated PBMCs was performed under conditions
that favor lymphocyte migration, i.e., a 4 h incubation period
that allowed 10 × 106 PBMCs/ml to migrate through 5µm
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pores of a PVP-free polycarbonate membrane coated with
25µg/ml fibronectin (35). Migrated cells were fixed, colored with
Hemacolor solutions (Merck, Darmstadt, Germany) and counted
microscopically. Chemotactic indices were calculated as the ratio
of cells migrated to chemokine solution and cells migrated to
buffer solution.
Migration of HRMVE cells was evaluated using cell invasion-
migration (CIM) plates and the real-time cell analyzer double
plate xCELLigence instrument (RCTA-DP; xCELLigence System;
Acea Biosciences, San Diego, CA, USA) (32). For each
experiment, performed in duplicate, the cell indices after 15 h
migration were normalized to the cell index of unstimulated
endothelial cells (set at 100%).
In vivo Lymphocyte Extravasation
While being anesthetized using 3.75% (w/v) ketamine (Syntec,
Santano de Parnaíba, Brazil) and 0.25% (w/v) xylazine (Syntec)
in PBS, endotoxin-free (detection limit: 0.125 pg LPS per µg
chemokine) synthetic CXCL12 variants were injected into the
knee cavity of 8 weeks old C57BL/6 mice (Animal Care Center
of the Universidade Federal de Minas Gerais, Brazil). The mice
received water containing 1.7 mg/ml of the CD26 inhibitor
sitagliptin [Merck Sharpe & Dohme (MSD), Whitehouse Station,
NJ, USA] during 3 days prior to injection. Three hours after
the injection, the mice were sacrificed by a subcutaneous
injection of a ketamine/xylazine overdose. The cells that migrated
to the tibiofemoral articulation were harvested and counted
differentially (26). The in vivo protocols using laboratory animals
were reviewed and approved by the Animal Ethical Committee
of the University of Minas Gerais and Belgian, European and
Brazilian guidelines regarding laboratory animal handling were
followed.
Enzyme Incubations
CXCL12 and its nitrated variants, at a final concentration
of 5µM, were incubated for several time intervals with
CD26, carboxypeptidase M (CPM; R&D Systems) and matrix
metalloproteinase-9 (MMP-9) at final concentrations of,
respectively, 1.65 nM (5 U/L), 15 nM and 10 nM. The incubations
with CD26 and CPM were performed in a buffer containing
50mM Tris/HCl and 1mM EDTA at pH 7.5. A buffer containing
150mM NaCl, 50mM Tris and 10mM CaCl2 (pH 7.5) was used
for incubations with MMP-9. All incubations were performed at
37◦C. The reaction was stopped by adding 20 µl 0.1% (v/v) TFA.
Hereafter, samples were desalted using C18 ZipTips (Millipore)
and eluted with 50% (v/v) acetonitrile in 0.1% (v/v) formic
acid. The samples were injected in an Amazon Speed ETD mass
spectrometer (Bruker Daltonics) and analyzed using Bruker
deconvolution software. An abundance cut-off of 5% and a
minimum of four peaks per protein was maintained. Intensities
of the deconvoluted peaks were used to quantify the chemokine
after incubation.
Anti-HIV Assays
The inhibitory effect of the CXCL12 variants on the infection
of MT-4 cells with the CXCR4-using HIV-1 strain NL4.3 was
assessed. 5-fold dilutions of the CXCL12 variants were applied
to a flat-bottom 96-well plate, after which 7.5 × 104 MT-4 cells
were added in 50 µl medium. After adding 50 µl of diluted HIV-
1 stock (500 pg/ml p24 Ag), cells were incubated for 4 days until
a strong cytopathic effect was observed in the untreated HIV-
1-infected cells. Antiviral activity of the CXCL12 variants was
measured by the MTS method (36). IC50 values of the CXCL12
variants were calculated.
Statistical Analyses
All statistical analyses to determine differences between CXCL12
variants were performed using the Mann-Whitney U test.
RESULTS
Nitration of Tyr7 and Tyr61 of CXCL12 Was
Detected After Incubation With
Peroxynitrite
Since peroxynitrite can nitrate any amino acid with a ring
structure, we investigated whether additionally to the reported
Tyr7, nitrated Trp57 and/or Tyr61 could be detected without
complete degradation of intact protein. SDS-PAGE quality
control showed no protein degradation after a 1min incubation
with any of the used peroxynitrite concentrations. Nitration of
Tyr or Trp results in the addition of 45 Da to the protein,
whereas the charge remains the same. By mass spectrometry, we
detected that the molecular mass of CXCL12 was unaltered or
increased with 45 or 90 mass units, corresponding with none,
one or two nitrated residues. Proteins were fragmented using
collision-induced dissociation in the mass spectrometer in such
a way that only the Asp-Pro bond in the protein was cleaved.
This resulted in a NH2-terminal MS
2 fragment containing Tyr7
and a COOH-terminal MS2 fragment containing Trp57 and
Tyr61. The analysis of the mass of these fragments allowed to
determine whether they carried a nitrated amino acid and MS3
analysis enabled us to locate the position of nitration in the
COOH-terminal fragment, i.e., Trp57 or Tyr61. Using multiple
reaction monitoring (MRM), the eluate of the peroxynitrite-
incubated sample that was loaded on the HPLC was scanned
by automated MS2 for CXCL12 variants with none, one, two or
three additional nitro compounds. The results of the incubation
of CXCL12 with various peroxynitrite concentrations at room
temperature are shown in Figure 1. An incubation with 1µM
peroxynitrite did not nitrate CXCL12, whereas the amount
of single nitrated, [3-NT7]CXCL12 and [3-NT61]CXCL12,
and double nitrated CXCL12, [3-NT7/61]CXCL12, increased
gradually with peroxynitrite concentrations increasing from
10µM to 1mM. No CXCL12 with three nitrated amino acids
was detected.MS3 analysis on the COOH-terminalMS2 fragment
containing one nitro compound confirmed that Tyr61, and
not Trp57, was nitrated. No COOH-terminal CXCL12 MS2
fragment with two nitrated amino acids (90 mass units extra) was
detected. The same effect was observed by incubating CXCL12
with these peroxynitrite concentrations at 37◦C (Figure 1).
However, compared to room temperature more nitrated CXCL12
was generated in the same period of time when using 10 or
100µMperoxynitrite. The total amount of nitrated CXCL12 after
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FIGURE 1 | Detection of nitrated CXCL12 forms by MS2, following
peroxynitrite incubation. CXCL12 was incubated with concentrations ranging
from 1µM to 1mM peroxynitrite for 1min at room temperature (upper panel)
or 37◦C (lower panel). A sample of the reaction volume was analyzed using
RP-HPLC coupled to an ion trap mass spectrometer. The presence of
CXCL12, [3-NT7]CXCL12, [3-NT61]CXCL12 and [3-NT7/61]CXCL12 was
determined by measuring variant-specific peptide fragments after MS2
fragmentation of the intact protein. The amount of each nitrated CXCL12 form
is shown as the percentage of the sum of all detected CXCL12 forms.
incubation with 1mM peroxynitrite at 37◦C was 55%, similar to
the detected amount of nitrated CXCL12 after incubation with
1mM at room temperature.
Production of Synthetic CXCL12 Variants
With Nitration on Tyr61
Two new CXCL12 variants containing nitrated Tyr61 were
synthesized using Fmoc solid phase peptide synthesis: one form
with only Tyr61 nitrated, i.e., [3-NT61]CXCL12, and another
form with both Tyr7 and Tyr61 nitrated, i.e., [3-NT7/61]CXCL12.
The synthetic proteins were folded and purified by reversed-
phase (RP)-HPLC. The Mr of each of these forms was confirmed
by ion trap mass spectrometry (Figure 2). [3-NT61]CXCL12
FIGURE 2 | Mass spectrometric analysis of synthetic [3-NT61]CXCL12 and
[3-NT7/61]CXCL12. [3-NT61]CXCL12 and [3-NT7/61]CXCL12 were
synthesized, deprotected, folded and purified using RP-HPLC. Fractions that
contained pure protein with the correct relative molecular mass (Mr) were
selected and pooled. The averaged mass spectrum of the final pool of folded
and purified [3-NT61]CXCL12 and [3-NT7/61]CXCL12 are shown in the upper
and lower panel, respectively. The number of charges and mass to charge
ratios (m/z) of the detected ions are indicated, together with the ion intensities.
The inserts in both panels show the deconvoluted mass spectra with the Mr of
the uncharged proteins, as determined using Bruker deconvolution software.
and [3-NT7/61]CXCL12 had an experimental mass of 8,004.5
and 8,049.4, respectively (theoretical Mr 8,004.4 and 8,049.4,
respectively). Native CXCL12 and CXCL12 nitrated at Tyr7,
[3-NT7]CXCL12 were produced before (26).
Nitrated CXCL12 has Higher Affinity for
Chondroitin Sulfate Compared to Native
CXCL12
The binding affinities of [3-NT61]CXCL12 and [3-
NT7/61]CXCL12 for heparin and the binding affinities of
[3-NT7]CXCL12, [3-NT61]CXCL12, and [3-NT7/61]CXCL12
for chondroitin sulfate were compared to CXCL12. Whereas,
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FIGURE 3 | CXCL12 nitration enhances binding to plates coated with chondroitin sulfate, but not with heparin, Serial dilutions of CXCL12 (, filled squares),
[3-NT7]CXCL12 (, open squares), [3-NT61]CXCL12 (◦, open circles) and [3-NT7/61]CXCL12 (1, open triangles) were incubated in heparin-coated or chondroitin
sulfate-coated plates. Bound CXCL12 forms were detected using biotinylated anti-human CXCL12 and horse radish peroxidase-labeled streptavidin and represented
as the mean percentage (n = 3 for heparin, n = 7 for chondroitin sulfate, ±SEM) of the absorbance of 120 nM (for the heparin experiments) or 40 nM (for the
chondroitin sulfate experiments) CXCL12 (at λ = 450 nm). Statistically significant differences between the nitrated CXCL12 forms and native CXCL12 were determined
using the Mann-Whitney U test (*p < 0.05, **p < 0.01).
there was a tendency toward lower heparin binding for high
concentrations of [3-NT61]CXCL12 and [3-NT7/61]CXCL12,
there was only a significant difference in heparin binding between
120 nM of CXCL12 and [3-NT7/61]CXCL12. Chondroitin sulfate
binding, however, was significantly higher at 13 nM for [3-
NT7]CXCL12 and CXCL12 [3-NT61]CXCL12 and at 1.5, 4.5,
and 13 nM for [3-NT7/61]CXCL12 compared to the same
concentrations of CXCL12 (Figure 3). Steady state analysis of the
SPR binding kinetics on heparin (Figure 4) also showed similar
KD values for all CXCL12 forms. Whereas, the KD calculated for
CXCL12 on heparin was 125 nM, the KD for [3-NT
61]CXCL12
and [3-NT7/61]CXCL12 was 157 nM and 133 nM, respectively.
Binding of these nitrated CXCL12 forms to their 7TM
receptors CXCR4 and ACKR3 was tested in CXCR4-transfected
and ACKR3-transfected CHO cells (Figure 5). Competition of
CXCL12 and [3-NT61]CXCL12 with 12.5 nM of fluorescently
labeled CXCL12AF647 was comparable for both receptors. The
ability to compete with CXCL12AF647 for CXCR4 binding was
slightly reduced for [3-NT7/61]CXCL12 compared to CXCL12,
whereas no significant differences were detected between these
forms regarding ACKR3 binding. This comparable binding is
demonstrated by a representative flow cytometry experiment
showing raw data for each of the receptors (Figure 5).
β-Arrestin 2 Recruitment to CXCR4, but not
to ACKR3, Is Reduced for
[3-NT7/61]CXCL12
In addition to receptor binding, the ability of CXCL12, [3-
NT61]CXCL12, and [3-NT7/61]CXCL12 to induce internalization
of CXCR4 was investigated using antibody clones 12G5 and
44717 and compared. The dose-dependent capacity of the three
CXCL12 forms to induce CXCR4 internalization on CXCR4
transfected CHO cells detected with anti CXCR4 clone 12G5
is shown in Figure 6 (upper panel). A comparable receptor
internalization was detected with antibody clone 44717 upon
treatment of CHO CXCR4 cells with 375 nM CXCL12 than with
clone 12G5 (Figure 6 upper panel and data not shown). Only at
37.5 nM [3-NT7/61]CXCL12 was significantly weaker at inducing
CXCR4 internalization than native CXCL12. Up to 375 nM
CXCL12 failed to induce significant CXCR4 internalization on
THP-1 cells (data not shown). Since receptor internalization is
mediated by recruiting β-arrestin to the cell membrane and [3-
NT7]CXCL12 recruited β-arrestin 2 less efficiently than CXCL12
(26), we tested how [3-NT61]CXCL12 and [3-NT7/61]CXCL12
compared to CXCL12 regarding β-arrestin 2 recruitment
(Figure 6 middle and lower panel). Whereas, no difference in
β-arrestin 2 recruitment to ACKR3 was measured among these
CXCL12 forms, [3-NT7/61]CXCL12 recruited significantly less
β-arrestin 2 to CXCR4 compared to native CXCL12.
[3-NT7/61]CXCL12 Shows a Reduced
Calcium Signaling Potency Compared to
Native CXCL12
CXCL12, [3-NT61]CXCL12 and [3-NT7/61]CXCL12 were
compared in several signaling pathways. The increase of
the intracellular calcium concentration ([Ca2+]i) following
stimulation of CXCR4 was measured in monocytic THP-1
cells and CXCR4-transfected CHO cells. In THP-1 cells, every
dose of CXCL12 induced a significantly higher increase of
[Ca2+]i compared to [3-NT
7/61]CXCL12. CXCL12 and [3-
NT61]CXCL12 were equally potent Ca2+ mobilizers (Figure 7
upper panel). Also on CHO-CXCR4 cells, [3-NT7/61]CXCL12
was significantly less potent to increase the [Ca2+]i compared
to CXCL12, whereas also on these cells [3-NT61]CXCL12 had a
similar potency as CXCL12 (Figure 7 lower panel).
Phosphorylation of the kinases Akt and ERK1/2 was
tested after stimulating CHO-CXCR4 cells for 2min with
various concentrations of CXCL12, [3-NT61]CXCL12 and
[3-NT7/61]CXCL12 (Figure 8 upper panels). No significant
differences in Akt phosphorylation were measured when
Frontiers in Immunology | www.frontiersin.org 6 August 2018 | Volume 9 | Article 1933
Janssens et al. Peroxynitrite Treatment Impairs CXCL12 Activity
FIGURE 4 | Surface plasmon resonance reveals comparable binding to
heparin for unmodified and nitrated CXCL12. Surface plasmon resonance
(SPR) analysis of the interaction of several concentrations (15.63–500 nM) of
CXCL12, [3-NT61]CXCL12 and [3-NT7/61]CXCL12 with heparin-coated
sensor chips are shown. One representative experiment out of two is
displayed.
cells were stimulated for 2min with these CXCL12 forms.
Surprisingly, stimulation of CXCR4 for 2min with 125 and
375 pM [3-NT61]CXCL12 caused a significantly higher ERK1/2
phosphorylation compared to the same doses of CXCL12.
Similar potencies in inducing phosphorylation of ERK1/2 were
detected for CXCL12 and [3-NT7/61]CXCL12 after 2min. Longer
incubation of the cells resulted in more pronounced differences
between the three CXCL12 forms (Figure 8 lower panels). The
trend toward higher activity for [3-NT61]CXCL12 in Akt and
ERK phosphorylation assays after 2min was confirmed at later
time points. In addition, [3-NT7/61]CXCL12 was clearly less
potent than unmodified CXCL12 after 10min in both signaling
assays.
Finally, despite the clear differences in calcium signaling
that we observed in both THP-1 cells and CHO-CXCR4 cells,
stimulation of CXCR4-transfected COS-7 cells for 20, 40, 60 or
90min showed an equal ability of all CXCL12 forms to generate
and accumulate IP3 in the cytoplasm (Figure 9).
[3-NT7/61]CXCL12 Is Less Chemotactic for
Monocytic THP-1 Cells, Lymphocytes and
Endothelial Cells Compared to CXCL12
As a result of receptor activation, chemokines usually induce
chemotaxis of their target cells. Therefore, the chemotactic
potency of [3-NT61]CXCL12 and [3-NT7/61]CXCL12 for
monocytic THP-1 cells, lymphocytes and endothelial cells was
compared with that of CXCL12. Chemotaxis assays using THP-1
cells showed that both CXCL12 and [3-NT61]CXCL12 were
able to induce a significant monocyte chemotactic response at
any given dose (Figure 10 upper panel). [3-NT7/61]CXCL12
induced significant monocyte chemotaxis after stimulation with
doses of 1.25 nm and higher, with a maximal chemotactic index
of 2.8 ± 0.2. At 0.375, 3.75, and 12.5 nm, [3-NT7/61]CXCL12
was significantly less potent at inducing chemotaxis when
compared to CXCL12. THP-1 cell migration after stimulation
with [3-NT61]CXCL12 was significantly lower compared to
CXCL12 at 12.5 nM. On the other hand, a dose of 1.25 nM
[3-NT61]CXCL12 induced a significantly higher chemotactic
response compared to CXCL12. This was the result of a shift
of the typical bell-shaped dose response curve after stimulation
of THP-1 cells with [3-NT61]CXCL12 compared to the dose
response curve of THP-1 cell migration toward CXCL12. As a
result, the maximal chemotactic index was reached at a lower
dose of [3-NT61]CXCL12 than of CXCL12 (3.75 and 12.5 nM,
respectively). However, the maximal chemotactic response
was stronger for CXCL12 than for [3-NT61]CXCL12 at their
respective optimal dose (maximal chemotactic index of 6.2± 0.9
and 4± 0.4, respectively).
Chemotaxis of freshly isolated lymphocytes toward
various concentrations of CXCL12, [3-NT61]CXCL12 and
[3-NT7/61]CXCL12 was compared (Figure 10 middle panel).
Both CXCL12 and [3-NT61]CXCL12 induced lymphocyte
chemotaxis at all tested doses. [3-NT7/61]CXCL12 was able to
induce a significant chemotactic response at all doses higher
than 3.75 nM, and the maximal chemotactic index obtained
was 2.7 ± 0.7. CXCL12 was significantly more potent than
[3-NT7/61]CXCL12 in attracting lymphocytes at every applied
dose, except 375 nM. In vitro lymphocyte chemotaxis was
comparable for CXCL12 and [3-NT61]CXCL12 (maximal
chemotactic index of 4.3± 0.5 for CXCL12, compared to 4.8± 1
for [3-NT61]CXCL12).
Also the effect of tyrosine nitration on the capacity of CXCL12
to induce endothelial cell migration was tested (Figure 10 lower
panel). Whereas, CXCL12 significantly induced endothelial cell
migration at any given dose, the other three CXCL12 forms
only did so at doses of 12.5 nM and higher. CXCL12 was
significantly more potent at attracting endothelial cells compared
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FIGURE 5 | Binding of CXCL12 forms to CXCR4 and ACKR3. Binding of CXCL12 (, filled squares), [3-NT61]CXCL12 (◦, open circles) and [3-NT7/61]CXCL12 (1,
open triangles) to CXCR4 was tested by adding various concentrations (ranging from 3.75 to 375 nM) of these CXCL12 forms together with 12.5 nM CXCL12AF647 to
CHO cells transfected with CXCR4. Binding is expressed as average fluorescent intensity relative to maximal fluorescence, obtained by incubation of the cells with
12.5 nM CXCL12AF647 without competitor. Mean percentages (±SEM) are derived from eight independent experiments. Flow cytometry data from a representative
receptor binding experiment show the remaining fluorescence of CXCL12AF647 after competition with 37.5 nM CXCL12 (black line), 37.5 nM [3-NT61]CXCL12 (red
line) or 37.5 nM [3-NT7/61]CXCL12 (blue line). The histogram where only CXCL12AF647 was added to the cells (gray area) shows the maximal fluorescence. The
unstained control is shown as a dotted histogram. Similar binding experiments were performed using CHO cells transfected with ACKR3 (lower panels). Various
concentrations of CXCL12 (, filled squares), [3-NT61]CXCL12 (◦, open circles) and [3-NT7/61]CXCL12 (1, open triangles) were added together with 12.5 nM
CXCL12AF647 to compete for ACKR3 binding. Binding is expressed relatively to the maximal fluorescence of CXCL12AF647 alone (n = 4, ±SEM). Flow cytometry
data from a representative experiment show the remaining CXCL12AF647 fluorescence after competition with 37.5 nM of the various CXCL12 variants [color coding as
indicated in the upper panel]. Statistically significant differences between the nitrated CXCL12 forms and native CXCL12 were determined using the Mann-Whitney U
test (*p < 0.05).
to [3-NT7]CXCL12 and [3-NT7/61]CXCL12 at 12.5 nM. No
statistical differences were measured between CXCL12 and [3-
NT61]CXCL12.
Nitration of CXCL12 Reduces its
Lymphocyte Chemoattractant Activity in
vivo
The consequences of nitration on CXCL12-mediated lymphocyte
extravasation was also investigated in vivo. Several doses
of CXCL12, [3-NT61]CXCL12, and [3-NT7/61]CXCL12 were
injected into the tibiofemoral articulation of mice, after
which the recruited lymphocytes were recovered and counted
(Figure 11). To protect the injected CXCL12 from proteolytic
truncation by CD26 and its consequent inactivation, the mice
were given drinking water containing the CD26 inhibitor
sitagliptin from 48 h prior to the injection of chemokine
till the end of the experiment. All tested doses, except 125
pmol [3-NT7/61]CXCL12, caused a significant extravasation of
lymphocytes as compared to vehicle control. Injection of 125
pmol native CXCL12 resulted in the migration of a median
amount of 3 × 103 lymphocytes to the joint. This number
was significantly higher when compared to the extravasation
following the injection of 125 pmol [3-NT7/61]CXCL12 or [3-
NT61]CXCL12, attracting no lymphocytes and a median number
of 0.6× 103 lymphocytes, respectively. Although the injection of
375 pmol [3-NT7/61]CXCL12 significantly recruited lymphocytes
to the knee cavity (median number of 0.4 × 103 cells), the
number of recruited cells was significantly lower when compared
to the number of cells recruited after injection with 375 pmol
CXCL12 (median number of 2.4× 103 cells). The injection of 375
pmol [3-NT61]CXCL12 showed a trend of reduced lymphocyte
extravasation (median number of 1.4 × 103 cells) compared to
CXCL12. However, this difference was not statistically significant
(p= 0.06).
COOH-Terminal Nitration of CXCL12
Results in a Decreased Sensitivity for CD26
Cleavage
As mentioned before, an important mechanism to regulate the
activity of CXCL12 is enzymatic truncation of either its NH2-
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FIGURE 6 | Internalization of CXCR4 and recruitment of β-arrestin 2 to CXCR4
and ACKR3 following stimulation with native or nitrated CXCL12. CXCL12 (,
filled squares), [3-NT61]CXCL12 (◦, open circles) and [3-NT7/61]CXCL12 (1,
open triangles) were compared for their potency to induce CXCR4
internalization (upper panel) and to recruit β-arrestin 2 to CXCR4 and ACKR3
(lower panels). CHO-CXCR4 cells were incubated for 1 h at 37◦C with various
concentrations (from 3.75 to 375 nM) of the different CXCL12 forms (upper
panel). The remaining receptor expression of CXCR4 was measured using
specific CXCR4 antibodies (clone 12G5) and shown as an average fluorescent
intensity relative to the maximal fluorescence, obtained by measuring CXCR4
expression without ligand stimulation (n = 4, ±SEM). The recruitment of
β-arrestin 2 was measured in CXCR4-transfected C2C12 cells (n ≥ 4) and
ACKR3-transfected U2OS cells (n = 3) after stimulation with 10-fold serial
dilutions (0.01 nM−1µM) of the CXCL12 forms (lower panels). The mean
percentage (±SEM) of the maximal β-arrestin 2 recruitment with native
CXCL12 is shown. Statistical differences between native CXCL12 and the
nitrated CXCL12 forms were determined using the Mann-Whitney U test (*p <
0.05).
FIGURE 7 | Calcium mobilization following CXCR4 activation with different
forms of CXCL12. The increase of the intracellular calcium concentration
[Ca2+]i after stimulation of monocytic THP-1 cells (upper panel; n = 6; ±SEM)
and CXCR4-transfected CHO cells (lower panel; n = 7, ±SEM) with
concentrations ranging from 0.375 to 37.5 nM of CXCL12 (, filled squares),
[3-NT61]CXCL12 (◦, open circles) or [3-NT7/61]CXCL12 (1, open triangles)
was measured. Statistical analyses, comparing [3-NT61]CXCL12 and
[3-NT7/61]CXCL12 to CXCL12, were performed using the Mann-Whitney U
test (*p < 0.05, **p < 0.01).
or COOH-terminus. We tested the effect of nitration on the
susceptibility of CXCL12 to become enzymatically processed
by three enzymes that were reported to process CXCL12, i.e.,
CD26, CPM, and MMP-9. Figure 12 shows the results of the
incubation experiments where the conversions of CXCL12 and
its nitrated variants by CD26 (upper panel), CPM (middle panel),
and MMP-9 (lower panel) were measured. The half-life of the
tested CXCL12 variants for these enzymes were calculated and
are shown in Table 1. CXCL12 and [3-NT7]CXCL12 were rapidly
cleaved by CD26, with a half-life of <1min. [3-NT61]CXCL12
and [3-NT7/61]CXCL12 were cleaved slower by CD26, with a
half-life that was two to three times longer compared to the half-
life of unmodified CXCL12. All tested CXCL12 variants generally
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FIGURE 8 | Effect of CXCL12 nitration on phosphorylation of Akt and ERK following CXCR4 activation. The amount of phosphorylated second messengers Akt (left
panels) and ERK1/2 (right panels) was measured after a 2min stimulation (upper panels) of CXCR4-transfected CHO cells with CXCL12 (, filled squares),
[3-NT61]CXCL12 (◦, open circles) or [3-NT7/61]CXCL12 (1, open triangles) at concentrations between 3.75 pM and 1.25 nM. Alternatively, CXCR4-transfected CHO
cells were stimulated for 2–120min with 375 pM of the above mentioned CXCL12 forms (lower panels). The average accumulation (n = 6–8, ±SEM) of
phosphorylated Akt and ERK1/2 was calculated as a percentage of vehicle-stimulated control. Statistical analyses, comparing [3-NT61]CXCL12 and
[3-NT7/61]CXCL12 to CXCL12, were performed using the Mann-Whitney U test (*p < 0.05).
showed a similar susceptibility to proteolytic cleavage by CPM
or MMP-9. For CPM, the half-life varied between 7 and 9.8min,
whereas cleavage by MMP-9 occurred slower with a half-life
ranging from 17 to 21min.
NH2-Terminal Nitration of CXCL12
Reduces its Anti-HIV-1 Activity
Besides CCR5, CXCR4 is a main co-receptor for HIV-1 infection.
Since CXCL12 is a natural competitor for HIV-1 gp120 binding
to CXCR4, the effect of tyrosine nitration on its antiviral activity
was investigated on lymphocytic MT-4 cells using the CXCR4-
tropic NL4.3 HIV-1 strain. A representative experiment of the
inhibition of HIV-1 replication by the CXCL12 forms is shown
in Figure 13. A summary of the IC50 values of the CXCL12
forms, calculated for two independent experiments is depicted
in Table 2. The small-molecule CXCR4 inhibitor AMD3100 was
used as a positive control and showed an average IC50 of 7.9 nM.
CXCL12 inhibited HIV-1 NL4.3 replication with an average IC50
of 70.5 nM. [3-NT61]CXCL12 had a slightly better anti-HIV-1
activity, with an IC50 of 41 nM. In contrast, nitration of Tyr7 or
both Tyr residues resulted in a lower anti-HIV-1 activity, with
average IC50 values of 125 nM for [3-NT
7]CXCL12 and 180 nM
for [3-NT7/61]CXCL12.
DISCUSSION
Peroxynitrite is a short-lived oxidizing reagent that is generated
through the interaction of nitric oxide and superoxide anions.
Production of these molecules occurs during the oxidative
response of macrophages, eosinophils and neutrophils as a
response to tumoral or microbial stress or during reperfusion
injury (37). Due to the unstable character and therefore short
half-life (<10ms) of peroxynitrite, at physiological pH, a
direct determination of peroxynitrite concentrations in vivo is
difficult. Peroxynitrite concentrations are estimated to be in
the nanomolar range. However, due to continuous production
and release, these concentrations can be maintained for hours
(38). Peroxynitrite can nitrate amino acids that contain ring
structures, like Tyr and Trp (39). To study the effects of nitration
on proteins, they are usually incubated for a short time with
a bolus of highly concentrated peroxynitrite (concentrations
ranging from 10µM to 1mM) (30, 40, 41). Specific nitrotyrosine
antibodies have been developed and the presence of nitrotyrosine
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FIGURE 9 | Accumulation of IP3 following CXCR4 activation with different forms of CXCL12. Accumulation of IP3 was measured in the cytoplasm after 20, 40, 60 (all
n = 2), or 90 (n = 6, ±SEM) min stimulation of CXCR4 with serial dilutions of CXCL12 (, filled squares), [3-NT61]CXCL12 (◦, open circles) or [3-NT7/61]CXCL12 (1,
open triangles).
in tissues is considered as a marker of inflammation since it is the
result of the coexistence of reactive nitrogen and oxygen species.
Co-localization studies showed that areas with nitrotyrosine
and CCL2 immunoreactivity coincided in kidney tissue sections
of ischemia and reperfusion-induced acute tubular necrosis
patients (41). In tissue sections of human colon and prostate
carcinoma, nitrated CCL2 was detected using nanobodies (30).
In vitro Tyr nitration by incubation with peroxynitrite was
detected for CCL2, CCL3, CCL5, CCL11, CXCL8 and CXCL12
(30, 40–45). Nitration of CXCL12 was also described to occur
in vitro by co-culture of bone marrow cells and leukocytes
when inflammatory stimuli were added to the cell medium
(26). Both eosinophil chemotaxis toward CCL5 and CCL11 and
migration of monocytes and neutrophils toward CCL3 were
reduced after incubation of these chemokines with peroxynitrite
(42–44). Regarding CCL2, Molon and colleagues showed an
abolished CD8+ T cell migration, whereas Barker and colleagues
reported only a reduced T cell chemotaxis after incubation of
the chemokine with peroxynitrite (30, 41). Monocyte chemotaxis
was reduced as a result of CCL2 nitration (30, 40, 41). Also
the migration of lymphocytes and monocytes to CXCL12 was
reduced as a consequence of Tyr nitration (26, 30).
In the published studies in which peroxynitrite was incubated
with recombinant chemokines, the presence of nitrotyrosine
was detected using direct ELISA assays or MS2 analyses
of tryptic digests. The aim of the present study was to
detect the appearance of nitrotyrosine in intact CXCL12 after
incubation with peroxynitrite since we noticed that also complete
degradation of chemokines may occur upon treatment with
peroxynitrite (data not shown). We confirmed the presence
of nitration on Tyr7, Tyr61, or both, but importantly not on
Trp. This indicates that although not specific for one of the
two Tyr amino acids, Tyr is more sensitive to modification
than Trp. The percentage of nitrated CXCL12 gradually
increased as the applied peroxynitrite concentrations were
elevated. At 1mM, peroxynitrite nitrated approximately 55%
of the detected CXCL12. To be able to evaluate biochemical
and biological characteristics, additional CXCL12 variants
containing a nitration on Tyr61, i.e., [3-NT61]CXCL12 and
[3-NT7/61]CXCL12, were chemically synthesized, folded and
purified by reversed-phase HPLC.
To gain further knowledge on the effects of tyrosine
nitration on CXCL12 activity, CXCL12, [3-NT7]CXCL12, [3-
NT61]CXCL12, and [3-NT7/61]CXCL12 were tested in in vitro
and in vivo biological assays. [3-NT7]CXCL12, [3-NT61]CXCL12,
and [3-NT7/61]CXCL12 had a similar heparin, CXCR4 and
ACKR3 binding affinity when compared to CXCL12 (26).
However, remarkably, compared to CXCL12, we measured an
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FIGURE 10 | In vitro monocytic, lymphocyte and endothelial cell chemotaxis
toward CXCL12 and its nitrated variants. CXCL12 (, filled squares),
[3-NT61]CXCL12 (◦, open circles) and [3-NT7/61]CXCL12 (1, open triangles)
were compared for their ability to induce chemotaxis of monocytic THP-1 cells
(top panel; n ≥ 7) and freshly isolated lymphocytes (middle panel, n ≥ 7). The
data are represented by chemotactic indices (mean ± SEM). In vitro migration
of endothelial cells (lower panel) was investigated by measuring the changes in
electrical impedance caused by cellular migration after stimulation of the cells
with CXCL12 (white bars), [3-NT7]CXCL12 (black bars), [3-NT61]CXCL12
(gray bars) and [3-NT61]CXCL12 (striped bars). The data are represented as a
mean percentage (n ≥ 4, ±SEM) of cell migration compared to spontaneous
migration. Statistical comparison between CXCL12 and its nitrated forms was
performed with the Mann-Whitney U test (*p < 0.05, **p < 0.01).
increased affinity of [3-NT7]CXCL12, [3-NT61]CXCL12, and [3-
NT7/61]CXCL12 for another GAG, i.e., chondroitin sulfate. For
several chemokines it has been shown that binding affinities
for GAGs greatly vary depending on the used GAG (46).
FIGURE 11 | In vivo lymphocyte extravasation to the articular cavity following
injection of native and nitrated CXCL12. Vehicle, CXCL12, [3-NT61]CXCL12 or
[3-NT7/61]CXCL12 (125 and 375 pmol) were injected in 10 µl into the knee
cavity of C57BL/6 mice that were treated for 48 h with the CD26 inhibitor
sitagliptin (added to the drinking water). Three hours after injection, recruited
leukocytes were counted differentially on May-Grünwald-Giemsa stained
cytospins. Each symbol represents an individual mouse (n ≥ 5). The median
number of migrated lymphocytes is shown as a horizontal line. Statistical
analysis comparing CXCL12 with [3-NT61]CXCL12 and [3-NT7/61]CXCL12
was performed using the Mann-Whitney U test (**p < 0.01; ***p < 0.001).
Here, we show that post-translational nitration of CXCL12
increases its affinity for chondroitin sulfate, whereas the
affinity for heparin remains similar for nitrated and native
CXCL12. Internalization of CXCR4 after stimulation with [3-
NT7/61]CXCL12 and the earlier described [3-NT7]CXCL12 was
similar, showing a reduced potency to internalize CXCR4 at
intermediate concentrations (26). Recruitment of β-arrestin 2
after stimulation of CXCR4 with [3-NT7]CXCL12 and [3-
NT7/61]CXCL12 was also significantly reduced, explaining the
moderately diminished receptor internalization [Figure 6 and
(26)]. However, β-arrestin 2 recruitment to ACKR3 remained
unaltered for all CXCL12 forms indicating that modification of
CXCL12 has more profound effects on its signaling through
CXCR4 than ACKR3 and induces at least a partial receptor bias.
In general and in contrast to nitration of Tyr7 (26), nitration
of Tyr61 did not negatively influence signal transduction
but even showed a moderately enhanced potency to induce
phosphorylation of the second messengers Akt and ERK. [3-
NT7/61]CXCL12 was significantly weaker in inducing an increase
in intracellular calcium and phosphorylation of Akt and ERK
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FIGURE 12 | Truncation of CXCL12 and its nitrated variants by CD26, CPM,
and MMP-9. A final concentration of 5µM CXCL12 (, filled squares),
[3-NT7]CXCL12 (, open squares), [3-NT61]CXCL12 (◦, open circles) or
[3-NT7/61]CXCL12 (1, open triangles) was incubated with CD26 (1.65 nM or 5
U/L) (upper panel), CPM (15 nM) (middle panel) or MMP-9 (10 nM) (lower panel)
at 37◦C. The incubated samples were desalted on C18 ZipTips and analyzed
by mass spectrometry. The graphs show the mean percentage conversion
(±SEM) of intact chemokine in function of time (n = 3 for CD26, n = 2 for CPM
and MMP-9). CPM, carboxypeptidase M; MMP-9, matrix metalloproteinase-9.
when compared to native CXCL12. Surprisingly, nitration of
CXCL12 did not result in a different potency to induce IP3
recruitment to the cytoplasm of COS-7 cells despite the clear
effects in calcium assays on both THP-1 cells and CHO-CXCR4
transfectants. Although different cells were used in this assay
and the expression levels of CXCR4 were lower on COS-7
compared to CHO cells (data not shown), we do not have a
clear explanation for this since IP3 recruitment was evaluated at
multiple concentrations and after different incubation periods.
The reduced signaling potency was translated into a reduced
THP-1 monocyte and lymphocyte in vitro chemotaxis toward
[3-NT7/61]CXCL12 compared to CXCL12, as was previously
described for the NH2-terminally nitrated [3-NT
7]CXCL12 (26).
Since CXCL12 is a proangiogenic factor and tyrosine nitration
was detected in kidney tissues after ischemia reperfusion injury,
we also tested whether endothelial cell migration toward CXCL12
was altered by tyrosine nitration (41, 47). Chemotaxis of
endothelial cells following stimulation with [3-NT7]CXCL12
and [3-NT7/61]CXCL12 was significantly reduced, whereas
endothelial cell migration toward [3-NT61]CXCL12 was similar
to endothelial chemotaxis toward CXCL12.
Remarkably, whereas CXCL12 and [3-NT61]CXCL12 showed
similar in vitro characteristics, 125 pmol [3-NT61]CXCL12
attracted significantly less lymphocytes to the tibiofemoral
articulation compared to 125 pmol CXCL12. Also a non-
significant trend (p = 0.06) of lower numbers of extravasated
lymphocytes toward 375 pmol [3-NT61]CXCL12 compared to
375 pmol CXCL12 was observed. Similar to the previously
described [3-NT7]CXCL12 (26), injection of [3-NT7/61]CXCL12
in the knee joint attracted only very low numbers of lymphocytes
at any given dose. Barker and colleagues observed reduced
monocyte chemotaxis in in vivo air pouch experiments as a result
of CCL2 nitration. They attributed this effect to a reduced heparin
and heparan sulfate binding capacity of the nitrated CCL2 (41).
We showed that heparin binding properties of [3-NT61]CXCL12
and [3-NT7/61]CXCL12 were similar to CXCL12 in this study.
Also in our previous study, [3-NT7]CXCL12 had similar binding
potencies to heparin, heparan sulfate and dermatan sulfate (26).
Previously, we also observed more profound differences in vivo
compared to in vitro for other post-translationally modified
chemokines. Truncated CXCL5 was 3 to 10-fold more potent
than intact CXCL5 in vitro. However, in order to be active in vivo,
proteolytic cleavage of CXCL5 was essential (48). Citrullinated
CXCL8 was almost equally potent as unmodified CXCL8 in
in vitro signaling and chemotaxis assays but failed to recruit
neutrophils in vivo (49). We did not observe a difference in
degradation between the CXCL12 forms upon incubation with
peroxynitrite. However, the addition of a nitro group to Tyr7
or both Tyr7 and Tyr61 significantly increased the affinity of
CXCL12 for chondroitin sulfate. This GAG is highly abundant
in cartilage and in the used in vivo model, CXCL12 was injected
in the knee cavity. CXCL12 or the nitrated variants are thus
expected to interact with chondroitin sulfate. The in vivo activity
of CXCL12 depends on its interaction with CXCR4, ACKR3
and GAGs. Although difficult to prove, our data suggest that
the altered chondroitin sulfate interaction may at least partially
explain the in vivo differences. The effect of GAGs on the activity
of chemokines is highly complex. GAG-binding is required for
in vivo activity (50). GAG-binding has been reported also to
protect CXCL12 and CXCR3 ligands from cleavage by CD26
(51, 52). However, in our in vivo experiments this protease
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TABLE 1 | Half-lives of CXCL12, [3-NT7]CXCL12, [3-NT61]CXCL12 and
[3-NT7/61]CXCL12 after incubation with CD26, CPM, or MMP-9.
Half-life (min)
CD26 CPM MMP-9
CXCL12 0.6 7 16.9
[3-NT7]CXCL12 0.8 8.4 20.8
[3-NT61]CXCL12 1.8 9.7 21.2
[3-NT7/61]CXCL12 1.5 9.8 18.5
CPM, carboxypeptidase M; MMP-9, matrix metalloproteinase-9.
FIGURE 13 | Anti-HIV-1 activity of nitrated CXCL12 forms. Serial dilutions of
CXCL12, (, filled squares), [3-NT7]CXCL12 (, open squares),
[3-NT61]CXCL12 (◦, open circles) and [3-NT7/61]CXCL12 (1, open triangles)
ranging from 0.2 to 375 nM were incubated with lymphocytic MT-4 cells at the
moment of infection with the HIV-1 strain NL4.3. Mean percentages of the
inhibition of HIV-1 replication were calculated from triplicate cultures. One
representative experiment out of two is shown.
was inhibited with sitagliptin. Multiple proteases have been
reported to be able to process CXCL12 (23). Although in the few
investigated cases GAG-binding appears to protect chemokines
from cleavage, it is unknown whether GAGs influence the
sensitivity of CXCL12 to the more than 10 proteases reported to
process this chemokine.Moreover, the sameGAGs that protected
CXCR3 ligands from cleavage by CD26 directly reduced the
GPCR-dependent signaling activity of CXCR3 ligands (52). This
indicates that depending on the local context, GAG-interactions
may stabilize chemokines or inhibit GPCR-dependent signaling
activity. In addition, the tighter interaction of the nitrated
CXCL12 with chondroitin sulfate may make the NH2-terminus
less available for receptor activation. Further investigations need
to be performed to elucidate how thismore thorough chondroitin
sulfate binding could result in reduced in vivo activity.
Since proteases are known to regulate CXCL12 activity, we
tested how nitration of CXCL12 influences its susceptibility
to cleavage by CD26, CPM, and MMP-9. CXCL12 and [3-
NT7]CXCL12 had a comparable half-life to previously described
values (53). However, the half-life of [3-NT61]CXCL12 and
[3-NT7/61]CXCL12 was two to three times longer. Thus,
TABLE 2 | Anti-HIV activity of CXCL12 and its nitrated variants in lymphocytic
MT-4 cells.
Experiment 1 (IC50, nM) Experiment 2 (IC50, nM)
CXCL12 87 54
[3-NT7]CXCL12 151 99
[3-NT61]CXCL12 41 41
[3-NT7/61]CXCL12 201 159
AMD3100 7.8 8
although CD26 cleaves a dipeptide from the NH2-terminus, its
activity is negatively influenced by COOH-terminal nitration.
As mentioned before, in our in vivo model we inhibited CD26
activity with sitagliptin, making it unlikely that the activity of
CD26 could explain the observed reduction in CXCL12 activity
in vivo after COOH-terminal nitration. We further confirmed
that CXCL12 is processed by CPM and additionally specified that
the half-life of its C-terminus under physiological conditions was
±7min (54). Nitration of any of the tyrosine residues did not
alter the susceptibility of CXCL12 to CPM-mediated processing
significantly, with a half-life of the nitrated variants ranging from
±8.4 to ±9.8min. Truncation of CXCL12 by several MMPs was
discovered previously (55). We further specified that the half-
life of CXCL12 for MMP-9 under physiological conditions was
±17min and that nitration of CXCL12 did not influence its
processing rate by MMP-9.
Additionally, we tested the effects of nitration on the anti-
HIV-1 capacity of CXCL12. Previous studies already showed that
post-translational modifications may strongly affect the ability of
CXCL12 to inhibit HIV-1 infection. The enzymatic removal of
the two NH2-terminal amino acids by CD26 drastically reduced
the anti-HIV-1 potency of CXCL12 (56–58). Citrullination of
Arg8 also strongly reduced the anti-HIV-1 activity of CXCL12,
whereas citrullination of three or all five Arg residues completely
abolished competition with HIV-1 (25). Here, [3-NT61]CXCL12
showed a similar competition with HIV-1 compared to CXCL12,
whereas, [3-NT7]CXCL12 and [3-NT7/61]CXCL12 had a reduced
anti-HIV-1 activity. Compared to NH2-terminal truncation
or citrullination of CXCL12, NH2-terminal nitration only
moderately reduced competition with HIV-1. Accordingly, also
the effects of truncation and citrullination on receptor activation
and cellular migration were more drastic compared to the effects
of nitration of CXCL12. Since the CXCR4 binding affinity was
similar for all tested CXCL12 forms, the lower anti-HIV-1 activity
of [3-NT7]CXCL12 and [3-NT7/61]CXCL12 is probably due to
the decreased capacity to induce CXCR4 internalization.
Recently, it was shown that i.v. injected nitrated CCL2
significantly inhibited cellular migration toward CCL2-
containing air pouches (41). In view of this finding, the effects
of CXCL12 nitration might have more implications in vivo. As
CCL2 was shown to be nitrated after ischemia reperfusion injury,
other chemokines like CXCL12 could also be nitrated in similar
inflammatory events. Given its function as a stem and progenitor
cell chemoattractant, migration of these cell types by circulating
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nitrated CXCL12 might be inhibited and thus potentially hinder
tissue repair and revascularization after injury.
In conclusion, we showed that intact CXCL12 is nitrated on
Tyr7 and Tyr61, but not on Trp57. Nitrated CXCL12 showed
an increased chondroitin sulfate binding affinity, whereas the
heparin and receptor binding potency remained comparable
to native CXCL12. Post-translational nitration of Tyr7 or both
Tyr7 and Tyr61 resulted in a lowered CXCR4-mediated β-
arrestin 2 recruitment and subsequent CXCR4 internalization.
Contrary, β-arrestin 2 recruitment to ACKR3 remained the same
for all CXCL12 forms, indicating a bias toward internalization
via ACKR3. Moreover, calcium signaling, in vitro migration
of monocytes, lymphocytes and endothelial cells and anti-
HIV-1 potency were reduced after NH2-terminal Tyr nitration.
Nitration of any tyrosine residue did not significantly influence
the processing speed of CXCL12 by CPM and MMP-9,
whereas, remarkably, only COOH-terminal and not NH2-
terminal nitration resulted in CXCL12 variants that were less
efficiently cleaved by the aminopeptidase CD26. In vivo, nitration
of any Tyr residue resulted in a lowered lymphocyte extravasation
into the knee joint.
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